Regenxbio will initiate a pivotal program for subretinal delivery of RGX-314 in patients with wet age-related macular degeneration later this year, following the release of positive 1-year data from a phase 1/2a trial.
The company plans to advance to AAVIATE, a phase 2 trial of the drug, with patient enrollment beginning in the third quarter, according to a press release.
The phase 1/2a trial evaluated 42 patients with severe wet AMD who required frequent anti-VEGF injections. In five cohorts, the doses ranged from 3 × 109 GC per eye to (Read more...)
Uncategorized